Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
SeaStar Medical Holding Corporation: SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
SeaStar Medical Holding Corporation (Nasdaq: ICU) ("SeaStar Medical" or the "Company"), a commercial-stage medical device company developing proprietary solutions ...